指南与共识血栓与止血

美国血液学会2018年静脉血栓栓塞症管理指南:肝素诱导的血小板减少症

American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.
指南 / 共识 · Blood Adv · 2018-01-01

美国血液学会(ASH)组织多学科指南小组,采用GRADE方法制定肝素诱导的血小板减少症(HIT)诊断与管理循证指南,共形成33条推荐。强推荐包括使用4Ts评分而非整体判断估计HIT验前概率,以及低概率4Ts评分患者避免HIT实验室检测和经验性治疗;条件推荐包括急性HIT治疗中非肝素抗凝药的选择。

要点

  • 强推荐使用4Ts评分而非整体判断估计HIT验前概率。
  • 强推荐低概率4Ts评分患者避免HIT实验室检测和经验性治疗。
  • 条件推荐急性HIT治疗可在非肝素抗凝药(阿加曲班、比伐卢定、达那肝素、磺达肝癸钠、直接口服抗凝药)中选择。

核心结论

  • ASH 2018年HIT指南共形成33条推荐,覆盖无症状患者筛查、疑似HIT诊断与初始管理、急性HIT治疗及特殊情境。
  • 强推荐包括使用4Ts评分而非整体判断估计HIT验前概率,以及低概率4Ts评分患者避免HIT实验室检测和经验性治疗。
  • 条件推荐包括急性HIT治疗中非肝素抗凝药(阿加曲班、比伐卢定、达那肝素、磺达肝癸钠、直接口服抗凝药)的选择。

研究设计与样本

  • 美国血液学会(ASH)成立多学科指南小组,平衡利益冲突以最小化偏倚。
  • 麦克马斯特大学GRADE中心支持指南制定过程,包括更新或执行系统证据评价。
  • 小组按对临床医生和患者的重要性优先排序临床问题与结局。
  • 采用GRADE方法评估证据并形成推荐,推荐经公开评论。

主要发现

  • 指南小组就33条推荐达成一致。
  • 推荐涉及无症状患者HIT筛查、疑似HIT诊断与初始管理、急性HIT治疗及特殊情境。
  • 特殊情境包括心血管手术、经皮心血管介入、肾脏替代治疗和静脉血栓栓塞症预防。

关键数值与推荐

  • 强推荐使用4Ts评分而非整体判断估计HIT验前概率。
  • 强推荐低概率4Ts评分患者避免HIT实验室检测和经验性治疗。
  • 条件推荐急性HIT治疗中非肝素抗凝药(阿加曲班、比伐卢定、达那肝素、磺达肝癸钠、直接口服抗凝药)的选择。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction mediated by platelet-activating antibodies that target complexes of platelet factor 4 and heparin. Patients are at markedly increased risk of thromboembolism. OBJECTIVE: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about diagnosis and management of HIT. METHODS: ASH formed a multidisciplinary guideline panel balanced to minimize potential bias from conflicts of interest. The McMaster University GRADE Centre supported the guideline development process, including updating or performing systematic evidence reviews. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess evidence and make recommendations, which were subject to public comment. RESULTS: The panel agreed on 33 recommendations. The recommendations address screening of asymptomatic patients for HIT, diagnosis and initial management of patients with suspected HIT, treatment of acute HIT, and special situations in patients with acute HIT or a history of HIT, including cardiovascular surgery, percutaneous cardiovascular intervention, renal replacement therapy, and venous thromboembolism prophylaxis. CONCLUSIONS: Strong recommendations include use of the 4Ts score rather than a gestalt approach for estimating the pretest probability of HIT and avoidance of HIT laboratory testing and empiric treatment of HIT in patients with a low-probability 4Ts score. Conditional recommendations include the choice among non-heparin anticoagulants (argatroban, bivalirudin, danaparoid, fondaparinux, direct oral anticoagulants) for treatment of acute HIT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018. PMID: 30482768. doi:10.1182/bloodadvances.2018024489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。